拓扑替康联合铂类治疗晚期卵巢癌的疗效观察

目的:评价拓扑替康联合铂类(TPT+铂类)治疗晚期卵巢癌的疗效及安全性。方法:回顾分析2000年4月至2004年12月收治的符合入选标准的晚期卵巢上皮性癌患者45例,其中初治20例,复治25例。比较初治患者与同期收治的接受紫杉醇加铂类(TP方案)及环磷酰胺加铂类(PC方案)治疗者的临床有效率、中位无进展生存时间和中位生存时间。复治患者则比较一线经铂类或经紫杉醇治疗复发者的有效率、中位无进展生存时间和中位生存时间。结果:初治患者中,TPT+铂类组有效率为75.0%,中位无进展生存时间及中位生存时间分别为17.8月及29.7月,而TP组分别为82.5%,20.9月,35.3月,PC组分别71.4%,14.6月,27.8月,TPT加铂类组与TP组、PC组相比,差异无显著性(P>0.05)。复治患者中,总有效率为28.0%,一线经铂类或经紫杉醇治疗复发患者的有效率为33.3%、23.1%,中位无进展生存时间分别为11.3月、8.4月,中位生存时间分别为18.3月,17.3月,差异无显著性(P>0.05)。非血液性毒性轻微。结论:TPT联合铂类治疗晚期卵巢癌疗效肯定,特别是对复发病例有较好疗效,耐受性良好。

The efficacy analysis of topotecan plus platinum in patients with advanced ovarian epithelial carcinoma

Objective:To evaluate the efficacy and safety of topotecan(TPT) plus platinum in patients with advanced ovarian epithelial cancer.Methods:Forty five cases with ovarian epithelial cancer treated by topotecan and platinum from Apr.2000 to Dec.2004 were analyzed retrospectively,including initial patients 20 and recurred 25.Clinical efficacy,median progression free interval and median overall survival were compared in initial patients between TPT plus platinum group(TPT group) and taxol plus platinum(TP regimen) or cyclophosphamide plus platinum(PC regimen).For recurred ones,clinical efficacy,median progression free interval and median overall survival were compared between patients treated with platinum and patients treated with toxol as first-line chemotherapy before.Results:In initial patients,the overall response was 75.0%.In group TPT plus PDD,group TP and group PC,median progression free interval was 17.8,20.9 and 14.6 months respectively;median overall survival was 29.7,35.3 and 27.8 months(P>0.05).In recurrent patients,the overall response was 28.0%.Treated by the first line chemotherapy of platinum or taxol,the overall response,median progression free interval and median overall survival were 33.3% or 23.1%,11.3 or 8.4 months,18.3 or 17.3 months respectively(P>0.05).Nonhematological toxicities were mild.Conclusion:TPT combined with platinum is effective and well-tolerated in the treatment of advanced ovarian epithelial carcinoma,especially in recurrent patients.